The tweet was deleted by the author.
But we saved everything 🙂.
Cullinan Therapeutics announced new clinical data showing that zipalertinib achieved clinically meaningful intracranial antitumor activity in patients with EGFR exon 20 insertion or uncommon EGFR-mutated non-small cell lung cancer (NSCLC) with active central nervous system metastases.
The results, part of a partnership with Taiho Oncology, are set to be presented at ESMO26. The findings highlight ongoing research efforts into therapies targeting difficult-to-treat mutations in NSCLC.
View post on X Loading...
Cullinan Therapeutics recently began an NDA submission with the FDA for zipalertinib plus chemotherapy in NSCLC in partnership with Taiho Oncology, according to a previous company announcement. The company has also outlined fourth quarter 2026 milestones focused on advancing its immunology and oncology T cell engager portfolio, as detailed in a recent pipeline update. These initiatives reflect Cullinan's continued efforts to develop targeted cancer therapies.